Seres Therapeutics, Inc. announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and Jayne M. Gansler as Executive Vice President, Chief People Officer (CPO). Dr. Ege brings to the role of CTO more than 15 years of experience in the pharmaceutical industry with a focus on manufacturing and developing vaccines and biologics. He joins Seres after an extensive career at Merck, where he worked on a number of breakthrough, novel products with complex manufacturing. Dr. Ege joined Merck in 2003 and served in a variety of technical and leadership roles in R&D and manufacturing. He was most recently Global Lead for Digital Strategy in Merck’s Manufacturing Division, in charge of driving business optimization, leading digital innovation, and helping advance products to market. Dr. Ege also held roles as Executive Director of Vaccines & Biologics Manufacturing and Head of Commercial Manufacturing Operations during his time at Merck. Ms. Gansler brings to the newly created role of CPO more than 25 years of experience leading global human resources organizations in the biotechnology, pharmaceutical and medical device industries. Prior to joining Seres, Ms. Gansler was Senior Vice President, Head of Human Resources at ARIAD Pharmaceuticals and served as a key leader during a time of significant change that included the sale and integration of ARIAD with Takeda Pharmaceuticals. She served as Senior Vice President, Global Head of Human Resources for Genzyme, a Sanofi Company, following Sanofi’s acquisition of Genzyme Corporation and led the integration and rebuilding of the HR strategy for Genzyme, a Sanofi Company.
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).